Retrospectire Analysis of 107 Cases of Liver Injury Induced by TCM or Chemical Medicine
10.6039/j.issn.1001-0408.2016.23.12
- VernacularTitle:107例中药与化学药致药物性肝损伤的回顾性分析
- Author:
Zhixian CHEN
;
Gang QIN
- Publication Type:Journal Article
- Keywords:
Drug-induced liver injury;
TCM;
Chemical medicine;
Clinical features;
Retrospective analysis
- From:
China Pharmacy
2016;27(23):3204-3206
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for rational drug use. METHODS:107 patients with drug-induced liver injury (DILI)admitted to liver disease department of our hospital during Jan. 2011 to Dec. 2015 were divided into TCM group and chemi-cal medicine group according to the type of medicine. DILI clinical characteristics,prognosis,medicine types of DILI were com-pared and analyzed between 2 groups. RESULTS:47 cases of DILI were induced by TCM,which mainly were health care and body beauty medicines(19.1%),rheumatism and arthritis medicines(14.9%)and dermatological medicines(10.6%). 60 cases of DILI were induced by chemical medicine,which mainly were antineoplastics(21.7%),antimicrobial(20.0%)and antituberculot-ics (11.7%). Gender,average age,the time from primary medication to disease attack and clinical classification were no signifi-cant difference between 2 groups(P>0.05). The clinical manifestations of the 2 groups were similar,except that fatigue was more common in the TCM group,with statistical significance(P<0.05). The liver function indicators of TCM group as ALT,AST, TBIL and ALP were higher than those of chemical medicine group,while ALT and TBIL were significantly different between 2 groups(P<0.05). The liver injuries were more serious in the TCM group than in chemical medicine group,with statistical signifi-cance(P<0.05). After treatment,the prognosis and the prognosis of liver function indicator in 2 groups were not statistically sig-nificant(P>0.05). CONCLUSIONS:Doctors and pharmacists should cooperate to master medication indication strictly,develop ADR monitoring and conduct blood concentration monitoring of high-risk DILI medicines,especially the hepatotoxicity of TCM so as to reduce the occurrence of DILI and guarantee the safety of clinical drug use.
